MBX Biosciences, Inc. (MBX)Healthcare | Biotechnology | Carmel, United States | NasdaqGS
60.04 USD
-1.01
(-1.654%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 55.97 -4.07 (-4.071%) ⇩ (July 13, 2026, 7:58 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 4:31 a.m. EDT
The recent price action is a dangerous illusion masking a fundamentally broken business. While the stock rallied sharply over the last two weeks, the underlying reality is stark: the company is burning cash at an accelerating rate with negative free cash flow and negative operating cash flow. The balance sheet is a facade; while debt is currently low, the liquidity is entirely dependent on capital markets, which are hostile to a company with negative earnings and no dividend history. The market's reaction to recent trial data—shares falling despite positive results—signals deep skepticism about the commercial viability of their pipeline. Crucially, the options market is screaming a warning that the current rally is a trap, with traders buying deep out-of-the-money puts to bet on a collapse. This disconnect between the short-term price bounce and the deteriorating operational metrics suggests the rally is a final capitulation before a significant re-rating. Investors should view this as a high-risk speculative vehicle rather than a turnaround story. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.128310 |
| AutoTheta | 0.128557 |
| AutoETS | 0.128737 |
| AutoARIMA | 0.128738 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 27% |
| H-stat | 4.44 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.010 |
| Excess Kurtosis | 0.16 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.127 |
| Market Cap | 2,857,756,160 |
| Forward P/E | -15.28 |
| Website | https://mbxbio.com |
As of July 11, 2026, 4:31 a.m. EDT: Speculators are aggressively positioning for a massive downside event, evidenced by the overwhelming concentration of out-of-the-money put open interest (OI) at strikes like $2.50, $15, and $40 for distant expirations. This 'naked put' strategy suggests a belief in a catastrophic failure or a severe de-rating of the asset class, rather than a standard hedging program. Conversely, call activity is sparse and clustered near the money, indicating a lack of speculative capital willing to bet on a recovery despite the recent price surge.
| Attribute | Value |
|---|---|
| 52 Week Change | 3.401586 |
| Address1 | 11,711 North Meridian Street |
| Address2 | Suite 300 |
| All Time High | 66.55 |
| All Time Low | 4.807 |
| Ask | 73.89 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 1,145,070 |
| Average Daily Volume3 Month | 796,140 |
| Average Volume | 796,140 |
| Average Volume10Days | 1,145,070 |
| Bid | 42.87 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 9.202 |
| City | Carmel |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 60.04 |
| Current Ratio | 30.791 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 60.88 |
| Day Low | 56.64 |
| Debt To Equity | 0.127 |
| Display Name | MBX Biosciences |
| Earnings Call Timestamp End | 1,754,564,400 |
| Earnings Call Timestamp Start | 1,754,564,400 |
| Earnings Timestamp | 1,778,157,000 |
| Earnings Timestamp End | 1,786,019,400 |
| Earnings Timestamp Start | 1,786,019,400 |
| Ebitda | -98,556,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -24.508 |
| Enterprise Value | 2,415,430,656 |
| Eps Current Year | -2.74794 |
| Eps Forward | -3.92862 |
| Eps Trailing Twelve Months | -2.13 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 39.4501 |
| Fifty Day Average Change | 20.589901 |
| Fifty Day Average Change Percent | 0.52192265 |
| Fifty Two Week Change Percent | 340.1586 |
| Fifty Two Week High | 66.55 |
| Fifty Two Week High Change | -6.510002 |
| Fifty Two Week High Change Percent | -0.09782121 |
| Fifty Two Week Low | 9.63 |
| Fifty Two Week Low Change | 50.41 |
| Fifty Two Week Low Change Percent | 5.234683 |
| Fifty Two Week Range | 9.63 - 66.55 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,726,234,200,000 |
| Float Shares | 27,054,915 |
| Forward Eps | -3.92862 |
| Forward P E | -15.28272 |
| Free Cashflow | -52,454,376 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 63 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02704 |
| Held Percent Institutions | 1.20592 |
| Implied Shares Outstanding | 47,597,536 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,024-09-13 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana. |
| Long Name | MBX Biosciences, Inc. |
| Market | us_market |
| Market Cap | 2,857,756,160 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_613097171 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -86,608,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,905,829,572 |
| Number Of Analyst Opinions | 11 |
| Open | 60.0 |
| Operating Cashflow | -77,479,000 |
| Operating Margins | 0.0 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 317 659 0200 |
| Post Market Change | -4.070801 |
| Post Market Change Percent | -6.7801476 |
| Post Market Price | 55.9692 |
| Post Market Time | 1,783,987,102 |
| Previous Close | 61.05 |
| Price Eps Current Year | -21.849094 |
| Price Hint | 2 |
| Price To Book | 6.5246687 |
| Profit Margins | 0.0 |
| Quick Ratio | 30.42 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.5 |
| Region | US |
| Regular Market Change | -1.01 |
| Regular Market Change Percent | -1.65438 |
| Regular Market Day High | 60.88 |
| Regular Market Day Low | 56.64 |
| Regular Market Day Range | 56.64 - 60.88 |
| Regular Market Open | 60.0 |
| Regular Market Previous Close | 61.05 |
| Regular Market Price | 60.04 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 632,139 |
| Return On Assets | -0.17676 |
| Return On Equity | -0.25731 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 47,597,536 |
| Shares Percent Shares Out | 0.123900004 |
| Shares Short | 5,895,340 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 4,811,025 |
| Short Name | MBX Biosciences, Inc. |
| Short Percent Of Float | 0.17379999 |
| Short Ratio | 5.62 |
| Source Interval | 15 |
| State | IN |
| Symbol | MBX |
| Target High Price | 91.0 |
| Target Low Price | 19.0 |
| Target Mean Price | 69.0 |
| Target Median Price | 70.0 |
| Total Cash | 439,976,992 |
| Total Cash Per Share | 9.244 |
| Total Debt | 555,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.13 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 31.6202 |
| Two Hundred Day Average Change | 28.419802 |
| Two Hundred Day Average Change Percent | 0.8987863 |
| Type Disp | Equity |
| Volume | 632,139 |
| Website | https://mbxbio.com |
| Zip | 46,032 |